Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference
DEVON, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) --
Zynerba Pharmaceuticals, Inc. (ZYNE), the
leader in innovative pharmaceutically-produced transdermal
cannabinoid therapies for rare and near-rare neuropsychiatric
disorders, today announced that Zynerba’s Chief Executive Officer,
Armando Anido will present a company overview at the 2019 BIO CEO
and Investor conference. The presentation will take place on
Monday, February 11, 2019 at 2:00 PM EST at the New York Marriott
Marquis. A live webcast of the presentation will be accessible on
the Investor Relations page of http://www.zynerba.com. A replay of
the webcast will be available for 90 days following the conclusion
of the event.
About Zynerba Pharmaceuticals,
Inc.
Zynerba Pharmaceuticals is the leader in pharmaceutically-produced
transdermal cannabinoid therapies for rare and near-rare
neuropsychiatric disorders. We are committed to improving the lives
of patients and their families living with severe, chronic health
conditions including Fragile X syndrome, Autism Spectrum Disorder,
22q11.2 Deletion Syndrome (22q), and a heterogeneous group of rare
and ultra-rare epilepsies known as developmental and epileptic
encephalopathies (DEE). Learn more at www.zynerba.com and
follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,†“believes,†“potential,†“proposed,†“continue,†“estimates,†“anticipates,†“expects,†“plans,†“intends,†“may,†“could,†“might,†“will,†“should†or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contact
William Roberts, Vice President, Investor Relations and Corporate
Communications
Zynerba Pharmaceuticals
484.581.7489
[email protected]
